Alport Syndrome

Alport syndrome is an inherited, progressive nephropathy caused by mutations in genes encoding components of the glomerular basement membrane, leading to structural damage and impaired kidney filtration and excretory function. GemPharmatech offers genetic models of Alport syndrome to support research into disease mechanisms and therapeutic development.

Advantages

Our Advantages

Industry-leading capabilities for alport syndrome research

Precisely recapitulates core pathogenic mechanisms of human Alport syndrome.

Homozygous knockout of Col4a3 disrupts the α3 chain of type IV collagen in the glomerular basement membrane, mirroring the genetic basis of hereditary Alport syndrome in patients.

Spontaneous, Progressive Disease Course

Chemical induction is not required for model establishment. As animals age, they spontaneously develop persistent proteinuria, glomerulosclerosis, tubulointerstitial fibrosis, and progressive renal function decline—faithfully replicating the human disease trajectory from microalbuminuria to severe proteinuria and ultimately end-stage renal failure.

Model Library

Comprehensive alport syndrome models for preclinical research

Case Studies

Case Studies & Validation Data

Explore our validated alport syndrome studies demonstrating the efficacy of various therapeutic interventions.

Col4a3-KO Spontaneous Alport Syndrome Model

Phenotypic Characterization of Col4a3-KO Mice and Standard of Care Drug Efficacy Evaluation

Learn more

Panel A Urine mALB and UACR (mALB/CREA) levels were markedly elevated in male Col4a3-KO mice, with levels rising progressively with age, indicative of impaired renal function.

Panel B Urine mALB and UACR (mALB/CREA) levels were markedly elevated in female Col4a3-KO mice, with levels rising progressively with age, indicative of impaired renal function.

Panel C Peripheral blood analysis revealed that 8-week-old male B6-Col4a3-KO mice displayed significant reductions in RBC (red blood cell), HGB (hemoglobin), RETIC-ABS (absolute reticulocyte count), and HCT (hematocrit), confirming an anemic phenotype.

Panel D Mice were treated with Ramipril, an ACE-inhibitor. Treatment was initiated in male mice at 4 weeks of age. Five weeks post-treatment, UACR levels were significantly lowered following ramipril intervention.

Statistical analysis was performed using one‑way ANOVA, and all data is presented as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001,****p<0.0001.

All Product

All Product Lines

Browse our comprehensive catalog of over 30,000 mouse models covering various gene families, signaling pathways, and disease models. Use advanced filters to find the perfect model for your research.